365 related articles for article (PubMed ID: 23566315)
1. Targeting mutant KRAS for anticancer therapeutics: a review of novel small molecule modulators.
Wang Y; Kaiser CE; Frett B; Li HY
J Med Chem; 2013 Jul; 56(13):5219-30. PubMed ID: 23566315
[TBL] [Abstract][Full Text] [Related]
2. A genome-wide RNAi screen identifies multiple synthetic lethal interactions with the Ras oncogene.
Luo J; Emanuele MJ; Li D; Creighton CJ; Schlabach MR; Westbrook TF; Wong KK; Elledge SJ
Cell; 2009 May; 137(5):835-48. PubMed ID: 19490893
[TBL] [Abstract][Full Text] [Related]
3. Challenges in Ras therapeutics in pancreatic cancer.
Choi M; Bien H; Mofunanya A; Powers S
Semin Cancer Biol; 2019 Feb; 54():101-108. PubMed ID: 29170065
[TBL] [Abstract][Full Text] [Related]
4. Mutations of the LIM protein AJUBA mediate sensitivity of head and neck squamous cell carcinoma to treatment with cell-cycle inhibitors.
Zhang M; Singh R; Peng S; Mazumdar T; Sambandam V; Shen L; Tong P; Li L; Kalu NN; Pickering CR; Frederick M; Myers JN; Wang J; Johnson FM
Cancer Lett; 2017 Apr; 392():71-82. PubMed ID: 28126323
[TBL] [Abstract][Full Text] [Related]
5. A gene expression signature of RAS pathway dependence predicts response to PI3K and RAS pathway inhibitors and expands the population of RAS pathway activated tumors.
Loboda A; Nebozhyn M; Klinghoffer R; Frazier J; Chastain M; Arthur W; Roberts B; Zhang T; Chenard M; Haines B; Andersen J; Nagashima K; Paweletz C; Lynch B; Feldman I; Dai H; Huang P; Watters J
BMC Med Genomics; 2010 Jun; 3():26. PubMed ID: 20591134
[TBL] [Abstract][Full Text] [Related]
6. Suppression of KRas-mutant cancer through the combined inhibition of KRAS with PLK1 and ROCK.
Wang J; Hu K; Guo J; Cheng F; Lv J; Jiang W; Lu W; Liu J; Pang X; Liu M
Nat Commun; 2016 May; 7():11363. PubMed ID: 27193833
[TBL] [Abstract][Full Text] [Related]
7. STK33 kinase inhibitor BRD-8899 has no effect on KRAS-dependent cancer cell viability.
Luo T; Masson K; Jaffe JD; Silkworth W; Ross NT; Scherer CA; Scholl C; Fröhling S; Carr SA; Stern AM; Schreiber SL; Golub TR
Proc Natl Acad Sci U S A; 2012 Feb; 109(8):2860-5. PubMed ID: 22323609
[TBL] [Abstract][Full Text] [Related]
8. KRAS and BRAF: drug targets and predictive biomarkers.
Vakiani E; Solit DB
J Pathol; 2011 Jan; 223(2):219-29. PubMed ID: 21125676
[TBL] [Abstract][Full Text] [Related]
9. Inhibitors of the Polo-Box Domain of Polo-Like Kinase 1.
Berg A; Berg T
Chembiochem; 2016 Apr; 17(8):650-6. PubMed ID: 26662918
[TBL] [Abstract][Full Text] [Related]
10. The PLK1 inhibitor GSK461364A is effective in poorly differentiated and anaplastic thyroid carcinoma cells, independent of the nature of their driver mutations.
Russo MA; Kang KS; Di Cristofano A
Thyroid; 2013 Oct; 23(10):1284-93. PubMed ID: 23509868
[TBL] [Abstract][Full Text] [Related]
11. Small-molecule inhibitors for targeting polo-like kinase 1.
Kolosenko I; Palm-Apergi C
Future Med Chem; 2020 Aug; 12(16):1457-1460. PubMed ID: 32638616
[No Abstract] [Full Text] [Related]
12. Small-molecular, non-peptide, non-ATP-competitive polo-like kinase 1 (Plk1) inhibitors with a terphenyl skeleton.
Mita Y; Noguchi-Yachide T; Ishikawa M; Hashimoto Y
Bioorg Med Chem; 2013 Feb; 21(3):608-17. PubMed ID: 23276450
[TBL] [Abstract][Full Text] [Related]
13. Synthetic lethal interaction between oncogenic KRAS dependency and STK33 suppression in human cancer cells.
Scholl C; Fröhling S; Dunn IF; Schinzel AC; Barbie DA; Kim SY; Silver SJ; Tamayo P; Wadlow RC; Ramaswamy S; Döhner K; Bullinger L; Sandy P; Boehm JS; Root DE; Jacks T; Hahn WC; Gilliland DG
Cell; 2009 May; 137(5):821-34. PubMed ID: 19490892
[TBL] [Abstract][Full Text] [Related]
14. Approaches to Ras signaling modulation and treatment of Ras-dependent disorders: a patent review (2007--present).
Sacco E; Spinelli M; Vanoni M
Expert Opin Ther Pat; 2012 Nov; 22(11):1263-87. PubMed ID: 23009088
[TBL] [Abstract][Full Text] [Related]
15. Small-molecule modulation of Ras signaling.
Spiegel J; Cromm PM; Zimmermann G; Grossmann TN; Waldmann H
Nat Chem Biol; 2014 Aug; 10(8):613-22. PubMed ID: 24929527
[TBL] [Abstract][Full Text] [Related]
16. STK33 kinase activity is nonessential in KRAS-dependent cancer cells.
Babij C; Zhang Y; Kurzeja RJ; Munzli A; Shehabeldin A; Fernando M; Quon K; Kassner PD; Ruefli-Brasse AA; Watson VJ; Fajardo F; Jackson A; Zondlo J; Sun Y; Ellison AR; Plewa CA; San MT; Robinson J; McCarter J; Schwandner R; Judd T; Carnahan J; Dussault I
Cancer Res; 2011 Sep; 71(17):5818-26. PubMed ID: 21742770
[TBL] [Abstract][Full Text] [Related]
17. Emerging role of the KRAS-PDK1 axis in pancreatic cancer.
Ferro R; Falasca M
World J Gastroenterol; 2014 Aug; 20(31):10752-7. PubMed ID: 25152578
[TBL] [Abstract][Full Text] [Related]
18. Targeting the RAS-dependent chemoresistance: The Warburg connection.
Serna-Blasco R; Sanz-Álvarez M; Aguilera Ó; García-Foncillas J
Semin Cancer Biol; 2019 Feb; 54():80-90. PubMed ID: 29432815
[TBL] [Abstract][Full Text] [Related]
19. PIK3CA mutation uncouples tumor growth and cyclin D1 regulation from MEK/ERK and mutant KRAS signaling.
Halilovic E; She QB; Ye Q; Pagliarini R; Sellers WR; Solit DB; Rosen N
Cancer Res; 2010 Sep; 70(17):6804-14. PubMed ID: 20699365
[TBL] [Abstract][Full Text] [Related]
20. A combination therapy for KRAS-mutant lung cancer by targeting synthetic lethal partners of mutant KRAS.
Pang X; Liu M
Chin J Cancer; 2016 Oct; 35(1):92. PubMed ID: 27793187
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
